MKI67 and neoplasm: In the monarchE trial, comparing standard adjuvant endocrine therapy to endocrine therapy plus abemaciclib in EBC patients with high-risk of relapse, the eligibility criteria included patients with 4 or more positive nodes or patients with 1 to 3 involved nodes plus an additional bad prognostic factor (tumor size ≥ 5 cm, grade 3 or centrally determined Ki67 ≥ 20%) [2].